Accuray (ARAY) Liabilities and Shareholders Equity (2011 - 2026)
Accuray's (ARAY) quarterly Liabilities and Shareholders Equity came in at $447.6 million in Q1 2026, up 137.41% year-on-year from $188.5 million in Q1 2025, and up 139.68% quarter-over-quarter from $186.7 million in Q4 2025.
Accuray (ARAY) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
Accuray's Liabilities and Shareholders Equity history runs 16 years deep, the most recent figure standing at $447.6 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 137.41% year-over-year to $447.6 million in Q1 2026; TTM through Mar 2026 was $1.3 billion, a 101.74% increase from a year earlier, with the FY2025 full-year figure at $470.2 million, up 229.7% from the prior year.
- Liabilities and Shareholders Equity grew to $447.6 million in Q1 2026 per ARAY's latest filing, from $186.7 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $470.2 million in Q2 2025 and bottomed at $90.7 million in Q2 2023.
- The 5-year median for Liabilities and Shareholders Equity is $121.3 million (2023), against an average of $168.8 million.
- Across the five-year window, Liabilities and Shareholders Equity dropped 1.31% in 2023 and soared 229.7% in 2025, its largest moves.
- Year by year, Liabilities and Shareholders Equity stood at $105.4 million in 2022, then advanced by 15.12% to $121.3 million in 2023, then soared by 31.08% to $159.0 million in 2024, then gained by 17.44% to $186.7 million in 2025, then surged by 139.68% to $447.6 million in 2026.
- Per Business Quant, the three latest ARAY Liabilities and Shareholders Equity figures stand at $447.6 million (Q1 2026), $186.7 million (Q4 2025), and $197.1 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Accuray | 29,832.96 | -38.50 Mn | 25.29 Mn | 447.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 447.60 Mn |
| Dec 31, 2025 | 186.75 Mn |
| Sep 30, 2025 | 197.12 Mn |
| Jun 30, 2025 | 470.24 Mn |
| Mar 31, 2025 | 188.54 Mn |
| Dec 31, 2024 | 159.01 Mn |
| Sep 30, 2024 | 155.06 Mn |
| Jun 30, 2024 | 142.63 Mn |
| Mar 31, 2024 | 114.93 Mn |
| Dec 31, 2023 | 121.31 Mn |
| Sep 30, 2023 | 108.08 Mn |
| Jun 30, 2023 | 90.74 Mn |
| Mar 31, 2023 | 104.17 Mn |
| Dec 31, 2022 | 105.37 Mn |
| Sep 30, 2022 | 92.18 Mn |
| Jun 30, 2022 | 91.94 Mn |
| Mar 31, 2022 | 93.48 Mn |
| Dec 31, 2021 | 84.46 Mn |
| Sep 30, 2021 | 81.93 Mn |
| Jun 30, 2021 | 54.52 Mn |